Reply: Trastuzumab Cardiotoxicity: No Need for Ejection Fraction Monitoring Without Prior Anthracycline Exposure [0.03%]
关于曲妥珠单抗心脏毒性的回信：既往未接受过蒽环类药物治疗者无需监测射血分数
Abdelrahman Ali,Anita Deswal
Abdelrahman Ali
Bonnie Ky
Bonnie Ky
Reply: Reconsidering the Oncologic Implications of Antihypertensive Therapy [0.03%]
关于抗高血压治疗的肿瘤学影响的再思考回复言论
Milad Nazarzadeh,Kazem Rahimi
Milad Nazarzadeh
Ioannis Skalidis,Henri Lu,Niccolo Maurizi et al.
Ioannis Skalidis et al.
Cardiovascular Risk Assessment in Patients With Kidney Cancer: Time for New Survivorship Goals [0.03%]
肾癌患者的血管风险评估：制定新的生存目标的时机到了
Kriti Mittal,Jenica N Upshaw
Kriti Mittal
Longitudinal Patterns of Cardiovascular Disease and Cancer Mortality in Renal Cell Carcinoma Patients by Tumor Stage [0.03%]
肾细胞癌患者中按肿瘤分期观察到的心血管疾病和癌症死亡率的纵向变化规律
Zhengyi Deng,Minji Jung,Mingyi Li et al.
Zhengyi Deng et al.
Background: Cardiovascular disease (CVD) is the leading cause of non-cancer deaths among patients with renal cell carcinoma (RCC). Objectives: ...
Lowering Blood Pressure, Raising Cancer Risk?: Evidence From Randomized Clinical Trials and Genetic Studies [0.03%]
降压与增癌风险？——随机临床试验和遗传学研究的证据
Fahmida Mannan,Marie Pigeyre
Fahmida Mannan
Shared Pathways, Shared Predictions: Cardiovascular Health and Risk Metrics in the Context of Cancer Risk [0.03%]
共通途径，共通预测：癌症风险下的心血管健康和风险指标
Ziwen Long,Wenying Gao,Xiang Gao
Ziwen Long